Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a purple berry calm kidney disease inflammation?

NCT ID NCT07776925

Disease control Sponsor: Universidad Mayor Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This trial tests whether a daily maqui berry supplement can improve gut health, reduce inflammation, and lower oxidative stress in people with stage 3-4 chronic kidney disease. Half of the 30 participants will take the maqui powder, while the other half receives a placebo, for three months. Researchers will compare changes in blood and stool markers between men and women to see if the berry's effects differ by sex.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
maqui berry extract (powdered supplement equivalent to 200 mg of Delphinol)
What this could lead to
If effective, maqui supplements could offer a natural, food-based way to help manage inflammation and gut health in people with chronic kidney disease, potentially slowing disease progression.
What could go wrong
This is a small, early-stage trial, so results may not apply broadly. The supplement may not produce meaningful changes, and its safety in this population is still being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women. * Age between 40 and 75 years. * Normal weight or overweight nutritional status. * Regular attendance at healthcare follow-up visits. * CKD stage 3-4 (eGFR 59-15) Exclusion Criteria: * Acute kidney injury within the three months preceding the intervention. * Inflammatory or infectious disease within the three months preceding the intervention. * Current smoking. * Use of oral anticoagulant therapy. * Pregnancy. * Current use of dietary supplements containing maqui. * Cancer. * Current antibiotic treatment or antibiotic use within the two weeks preceding the intervention.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease (stage 3-4) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease (stage 3-4)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Santiago

    Santiago, Santiago Metropolitan, 7770093, Chile

More trials for these conditions

Other studies related to the condition(s) this trial covers.